Less than 20% of patients with laboratory evidence of kidney disease are referred to nephrologists

NewsGuard 100/100 Score

Less than 20% of patients with laboratory evidence of kidney disease are referred for specialty care but most patients who are not referred have low predicted two-year risk of kidney failure.

Kidney disease guidelines for nephrology referral are transitioning from recommending referral based on laboratory value thresholds to using risk of kidney failure to guide referrals, but the impact on healthcare systems is not known.

Using data from the Veterans Health Administration, researchers estimated the potential volume of nephrology referrals based on laboratory data, the estimated risk of kidney failure, or a combination of both. In a study published in the American Journal of Kidney diseases, Vishal Duggal et al report that referral based on a two-year risk of kidney failure of 1% or higher would result in a similar number of referrals as current laboratory-based guidelines but would identify patients at higher median risk for kidney failure.

Source:
Journal reference:

Duggal, V., et al. (2021) Nephrology Referral Based on Laboratory Values, Kidney Failure Risk, or Both: A Study Using Veterans Affairs Health System Data. American Journal of Kidney Diseases. doi.org/10.1053/j.ajkd.2021.06.028.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 3 trial shows overall survival benefit from adjuvant therapy in kidney cancer patients